- Slice of Manufacturing
- Posts
- Charles River and AAVantgarde Partner to Produce GMP Plasmid DNA for Gene Therapy
Charles River and AAVantgarde Partner to Produce GMP Plasmid DNA for Gene Therapy
Slice of Manufacturing Team
July 11, 2024
Key Highlights:
Charles River and AAVantgarde collaborate on GMP plasmid DNA production.
Focus on AAVantgarde’s Stargardt’s disease program (AAVB-039).
Addresses unmet needs in inherited retinal diseases with no current therapies.
Charles River’s GMP plasmid DNA CDMO center of excellence in Keele, UK.
Expert roundtable on cell and gene therapy scalability available on demand.
Source (Business Wire)
Notable Quotes:
“Charles River is thrilled to produce GMP plasmid DNA to help advance AAVantgarde’s platform for the treatment of Stargardt’s disease – a condition in which there is high unmet need. Our team brings more than two decades of CDMO expertise, and we look forward to leveraging these capabilities to make a difference for patients.”
“By collaborating with Charles River, we are one step closer to beginning clinical trials to ensure our therapeutic product for Stargardt’s Disease is safe and efficacious for patients. We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to expanding treatment options for this patient population.”
Our Take:
This partnership between Charles River Laboratories and AAVantgarde marks a significant step forward in the field of gene therapy, particularly for addressing the unmet needs of patients with inherited retinal diseases like Stargardt’s disease. By leveraging Charles River’s extensive experience and advanced GMP manufacturing capabilities, AAVantgarde is well-positioned to progress its innovative AAV-intein platform towards clinical trials. The collaboration not only promises to enhance the delivery of large genes but also exemplifies the potential of strategic partnerships in accelerating the development of life-changing therapies.